Market Research Logo

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
  • The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics and enlists all their major and minor projects
  • The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Cognitive Impairment Associated With Schizophrenia (CIAS) Overview
Therapeutics Development
Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies
Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
AbbVie Inc.
Amarantus Bioscience Holdings, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bristol-Myers Squibb Company
Coronis Partners Ltd.
Eli Lilly and Company
FORUM Pharmaceuticals Inc.
H. Lundbeck A/S
Intra-Cellular Therapies, Inc.
Iproteos S.L.
Luc Therapeutics, Inc.
Neuralstem, Inc.
Pfizer Inc.
Saniona AB
SK Biopharmaceuticals Co., Ltd.
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Takeda Pharmaceutical Company Limited
Vanda Pharmaceuticals Inc.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-431404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-761 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQW-051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-4345 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-5736 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUT-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-3288 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
davunetide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-3748 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eltoprazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erteberel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FRM-17874 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-041 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPR-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPR-19 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPRO-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ITI-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2463359 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSN-2814617 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LUAF-64280 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-03463275 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-04958242 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNU-120596 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roflumilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-15508 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-A4R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize NMDA2B for Cognitive Impairment Associated With Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-14040 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-058 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-915 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
Featured News & Press Releases
Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a “RETOS-Colaboración” grant
Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
Feb 19, 2013: Intra-Cellular Therapies Completes Phase I Single Rising Dose Trial Of Selective Phosphodiesterase 1 Inhibitor
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AbbVie Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Company, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis Partners Ltd., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Company, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by H. Lundbeck A/S, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos S.L., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Luc Therapeutics, Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Neuralstem, Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Saniona AB, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed S.L., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects (Contd..1), H2 2016
Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report